ANKRD44 Gene Silencing: A Putative Role in Trastuzumab Resistance in Her2-Like Breast Cancer.
ANKRD44
Her2+ breast cancer
LC-MS/MS
Trastuzumab resistance
gene silencing
next generation sequencing
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2019
2019
Historique:
received:
19
02
2019
accepted:
04
06
2019
entrez:
13
7
2019
pubmed:
13
7
2019
medline:
13
7
2019
Statut:
epublish
Résumé
Trastuzumab is an effective therapeutic treatment for Her2-like breast cancer; despite this most of these tumors develop resistance to therapy due to specific gene mutations or alterations in gene expression. Understanding the mechanisms of resistance to Trastuzumab could be a useful tool in order to identify combinations of drugs that elude resistance and allow a better response for the treated patients. Twelve primary biopsies of Her2+/hormone receptor negative (ER-/PgR-) breast cancer patients were selected based on the specific response to neoadjuvant therapy with Trastuzumab and their whole exome was sequenced leading to the identification of 18 informative gene mutations that discriminate patients selectively based on response to treatment. Among these genes, we focused on the study of the ANKRD44 gene to understand its role in the mechanism of resistance to Trastuzumab. The ANKRD44 gene was silenced in Her2-like breast cancer cell line (BT474), obtaining a partially Trastuzumab-resistant breast cancer cell line that constitutively activates the NF-kb protein via the TAK1/AKT pathway. Following this activation an increase in the level of glycolysis in resistant cells is promoted, also confirmed by the up-regulation of the LDHB protein and by an increased TROP2 protein expression, found generally associated with aggressive tumors. These results allow us to consider the ANKRD44 gene as a potential gene involved in Trastuzumab resistance.
Identifiants
pubmed: 31297336
doi: 10.3389/fonc.2019.00547
pmc: PMC6607964
doi:
Types de publication
Journal Article
Langues
eng
Pagination
547Commentaires et corrections
Type : ErratumIn
Références
J Clin Oncol. 1999 Sep;17(9):2639-48
pubmed: 10561337
Oncogene. 2000 Feb 24;19(9):1123-31
pubmed: 10713699
Oncogene. 2000 Dec 11;19(53):6115-21
pubmed: 11156524
Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37
pubmed: 11252954
Cancer Res. 2001 Mar 15;61(6):2420-3
pubmed: 11289108
Oncogene. 2001 Mar 15;20(11):1287-99
pubmed: 11313873
J Natl Cancer Inst. 2001 Dec 19;93(24):1852-7
pubmed: 11752009
J Clin Oncol. 2002 Feb 1;20(3):719-26
pubmed: 11821453
Clin Cancer Res. 2001 Dec;7(12 Suppl):4436s-4442s; discussion 4411s-4412s
pubmed: 11916237
Int J Cancer. 2002 Jun 20;99(6):783-91
pubmed: 12115478
Cancer Res. 2002 Jul 15;62(14):4132-41
pubmed: 12124352
J Mol Biol. 2003 Feb 7;326(1):105-15
pubmed: 12547194
J Biol Chem. 2003 Sep 19;278(38):36916-23
pubmed: 12842894
Nat Rev Cancer. 2004 May;4(5):361-70
pubmed: 15122207
Cancer Cell. 2004 Aug;6(2):117-27
pubmed: 15324695
Cancer Res. 2005 Jan 15;65(2):473-82
pubmed: 15695389
Exp Cell Res. 2005 Apr 1;304(2):604-19
pubmed: 15748904
FEBS Lett. 2005 Aug 1;579(19):4149-58
pubmed: 16023111
Cancer Res. 2005 Dec 1;65(23):11118-28
pubmed: 16322262
Future Oncol. 2005 Dec;1(6):841-9
pubmed: 16556064
J Biol Chem. 2006 Dec 29;281(52):39891-6
pubmed: 17079228
N Engl J Med. 2007 Jul 5;357(1):39-51
pubmed: 17611206
Cancer Cell. 2007 Oct;12(4):395-402
pubmed: 17936563
Biochemistry. 2008 Feb 5;47(5):1442-51
pubmed: 18186651
Cell. 2008 Feb 8;132(3):344-62
pubmed: 18267068
Exp Cell Res. 2008 Sep 10;314(15):2725-38
pubmed: 18586026
Int J Cancer. 2009 Dec 15;125(12):2863-70
pubmed: 19609947
J Clin Oncol. 2009 Dec 1;27(34):5838-47
pubmed: 19884552
Clin Cancer Res. 2009 Dec 1;15(23):7196-206
pubmed: 19920112
Oncogene. 2010 Feb 25;29(8):1238-48
pubmed: 19946332
Cancer Res. 2011 Jan 1;71(1):13-8
pubmed: 21199794
FEBS J. 2011 Jun;278(12):2044-54
pubmed: 21481188
Cancer Res. 2011 Jul 1;71(13):4585-97
pubmed: 21498634
Clin Cancer Res. 2013 Jul 1;19(13):3703-13
pubmed: 23697991
Mol Cancer Res. 2014 Mar;12(3):433-9
pubmed: 24336958
Genes Cancer. 2013 Sep;4(9-10):342-59
pubmed: 24349632
Lancet. 2014 Jul 12;384(9938):164-72
pubmed: 24529560
Cancer Res. 2014 Aug 15;74(16):4295-305
pubmed: 24928782
J Clin Oncol. 2014 Nov 20;32(33):3744-52
pubmed: 25332249
Mol Syst Biol. 2014 Oct 30;10:757
pubmed: 25358341
Sci Signal. 2015 Mar 10;8(367):ra27
pubmed: 25759478
Genes Cancer. 2015 Mar;6(3-4):84-105
pubmed: 26000093
Sci Rep. 2015 Sep 18;5:14283
pubmed: 26381817
Am J Physiol Heart Circ Physiol. 2015 Nov;309(9):H1453-67
pubmed: 26386112
Monoclon Antib Immunodiagn Immunother. 2016 Feb;35(1):1-11
pubmed: 26871511
Elife. 2016 Apr 22;5:
pubmed: 27244671
J Proteome Res. 2016 Dec 2;15(12):4722-4730
pubmed: 27809536
Biochem Soc Trans. 2017 Jun 15;45(3):693-701
pubmed: 28620030
Int J Oncol. 2018 Aug;53(2):515-526
pubmed: 29901071
Oncol Rep. 2018 Aug;40(2):759-766
pubmed: 29901160
Biochim Biophys Acta Mol Cell Res. 2019 Jan;1866(1):74-82
pubmed: 30036567
Mol Oncol. 2019 Feb;13(2):358-375
pubmed: 30443978
Exp Mol Pathol. 2019 Apr;107:129-140
pubmed: 30763573
Oncol Lett. 2019 May;17(5):4710-4716
pubmed: 30944657
Nature. 1997 May 29;387(6632):512-6
pubmed: 9168115